What does the research say about gastric emptying?
Gastric emptying is the regulated transit of gastric contents into the duodenum. This page summarises preclinical and clinical research on the hormonal, neural and surgical factors that modulate it.
Gastric emptying is the process by which the stomach delivers its contents to the duodenum, and it is the rate-limiting step of digestion. In the research literature it is quantified most often as a half-time (T½), the time required for half of a test meal to leave the stomach, measured by standardized scintigraphy; related measures include route-specific gastric transit and the rate of emptying of solid versus liquid meals [4]. The term appears alongside gastroparesis (delayed emptying) and rapid gastric emptying, and it is treated as a physiological endpoint rather than a compound, so it carries no sequence, formula or molecular weight of its own. The work summarised here centres on the vagal brain-gut axis and on the incretin and amylin hormone systems, particularly GLP-1 receptor (GLP-1R) signalling and amylin receptor signalling, which act on gastric motor function alongside central satiety circuits [1][3][5].
Because gastric emptying is a shared endpoint, it is studied across several unrelated models: ovarian-hormone manipulation in rats, simulated microgravity in rats, bariatric and endoscopic surgical cohorts, and pharmacotherapy cohorts receiving incretin-based agents [1][2][4][7][8]. The sections below separate those contexts and state where the evidence is animal-only or otherwise indirect.
Research Studies
Oestrogen and stress-induced vagally-dependent gastric responses in female rats
In Sprague-Dawley female rats, gastric emptying was slower when oestrogen levels were high, and stress produced no further slowing under those conditions [1]. Whole-cell recordings in the same work found that oxytocin suppressed GABAergic transmission to dorsal motor nucleus of the vagus (DMV) neurons under non-stressed conditions regardless of oestrogen level — a result the authors contrast with earlier reports in male rats [1]. The study frames these findings within the observation that disorders of gut-brain interaction are more prevalent and often more severe in females [1]. This is animal-only evidence.
Amylin-based pharmacotherapy and slowing of gastric emptying
Amylin is a pancreatic β-cell hormone co-secreted with insulin. It contributes to postprandial glucose regulation, slows gastric emptying, suppresses glucagon secretion, and promotes satiation through central nervous system actions [3]. Long-acting amylin-based agents developed through peptide engineering, lipidation and reversible albumin binding include cagrilintide, eloralintide, petrelintide and NN1213, which differ in their pharmacokinetic properties [3]. The mechanisms described are distinct from those of incretin-based therapies [3].
GLP-1 receptor agonists and delayed gastric emptying
GLP-1 receptor agonists are described as mimicking the natural hormone glucagon-like peptide-1; they trigger pancreatic insulin release and delay gastric emptying [8]. Both short-acting (exenatide/exendin-4) and long-acting (liraglutide, dulaglutide, semaglutide) GLP-1R agonists have been approved for type 2 diabetes and/or obesity [5]. In preclinical work, systemic exendin-4 treatment reduced alcohol intake, motivation to consume alcohol, and relapse-like behaviour in male animals, with comparable reductions in alcohol consummatory behaviours in male or female animals treated with other agents [5]. That behavioural work is animal-only and is not a gastric-emptying measurement.
Endoscopic fundal mucosal ablation and gastric volume
The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways, and endoscopic gastric fundal mucosal ablation (GFMA) is proposed to act on both [2]. Ablation is also expected to shrink the fundus and reduce gastric volume, by analogy with mucosal ablation for other indications such as endoscopic submucosal dissection for tumour removal [2]. Gastric emptying is named as a separate potential target, on the basis that emptying has been found to be more rapid after prolonged exposure to a high-fat diet in both animal and human studies, and that rapid emptying is more common in some populations [2].
Transit bipartition after sleeve gastrectomy and solid-meal emptying half-time
A prospective, single-centre study is evaluating adults undergoing revisional conversion from sleeve gastrectomy to intestinal transit bipartition, with forty participants completing clinical, endoscopic, physiological, metabolic, hormonal, imaging and stool assessments before surgery and during follow-up [4]. The primary outcome is the within-participant change in solid-meal gastric emptying half-time (T½) measured by standardized scintigraphy from baseline to 6 months [4]. Secondary and exploratory outcomes include reflux symptoms, DeMeester score and acid exposure, route-specific gastric transit, GLP-1 and ghrelin responses, glucose metabolism, fecal elastase, gut microbiota and body-weight trajectory [4].
Simulated microgravity and functional dyspepsia in rats
Thirty male Wistar rats were randomly assigned to control, hindlimb-unloading (HU) and domperidone groups, with the HU model induced by 21-day tail suspension as a ground-based platform for simulating microgravity [7]. Behavioural tests included sucrose preference and novelty-suppressed feeding, alongside gastrointestinal motility and brain-gut peptide measures, in a model of simulated microgravity-induced functional dyspepsia [7]. This is animal-only evidence.
Mechanical ventilation-associated gastrointestinal dysfunction
In intensive care, more than 60% of mechanically ventilated patients experience gastrointestinal dysfunction [6]. Proposed contributors include increased intra-abdominal pressure from positive-pressure ventilation inhibiting gastrointestinal motility, inflammatory responses, prolonged bed rest, electrolyte imbalances, and the use of sedatives, analgesics and muscle relaxants [6]. Manifestations include gastroparesis and constipation [6]. A registered study is examining neostigmine acupoint injection at Zusanli (ST36) for mechanical ventilation-associated gastrointestinal dysfunction [6].
Comparison of emptying-related mechanisms across models
| Context | Model or population | Emptying-related finding |
|---|---|---|
| Oestrogen and stress [1] | Female Sprague-Dawley rats | Slower gastric emptying when oestrogen levels were high; no further effect of stress |
| Amylin-based agents [3] | Pharmacological review | Amylin slows gastric emptying; long-acting analogues include cagrilintide, eloralintide, petrelintide, NN1213 |
| GLP-1 receptor agonists [8] | Clinical study description | Agents delay gastric emptying and trigger insulin release |
| High-fat diet exposure [2] | Animal and human studies | More rapid emptying after prolonged high-fat diet exposure |
| Transit bipartition [4] | Adults post-sleeve gastrectomy | Primary outcome is change in solid-meal T½ by scintigraphy at 6 months |
| Simulated microgravity [7] | Male Wistar rats | Motility and brain-gut peptide alterations in a functional dyspepsia model |
Supporting pharmacovigilance and review literature
Additional work maps postmarketing safety signals and medication-use risks of GLP-1 receptor agonists and the GIP/GLP-1 co-agonist tirzepatide in diabetes and obesity care using an integrated pharmacovigilance, utilisation-context, regulatory and external-consistency framework [10]. A separate review covers digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies, noting that incretin-based pharmacotherapy, multi-receptor agonists and endoscopic bariatric procedures have expanded treatment options [11]. Another review examines how cholecystectomy and gastrectomy contribute to pancreatic cancer development, in the context of a 5-year survival rate of 2% to 9% and the need to understand modifiable risk factors [12]. Work on obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy and the oral microbiome describes reproducible oral microbiome dysbiosis mediated by pathways including chronic intermittent hypoxia-driven immune dysregulation, obligate mouth breathing causing salivary desiccation, and elevated salivary glucose promoting cariogenic biofilm [9]. These items support the wider context and are not gastric-emptying studies.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing here is a recommendation, a protocol, or a substitute for clinical advice. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Oestrogen modulates stress-induced vagally-dependent gastric responses to oxytocin — https://europepmc.org/article/PMC/PMC13577686
- [2] Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation — https://clinicaltrials.gov/study/NCT07612527
- [3] Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — https://pubmed.ncbi.nlm.nih.gov/42586227/
- [4] Transit Bipartition After Sleeve Gastrectomy — https://clinicaltrials.gov/study/NCT07728682
- [5] GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies — https://pubmed.ncbi.nlm.nih.gov/42461204/
- [6] Study on Neostigmine Acupoint Injection at Zusanli(ST36) for Treating Mechanical Ventilation-Associated Gastrointestinal Dysfunction — https://clinicaltrials.gov/study/NCT07692282
- [7] Tail-Suspension Model of Simulated Microgravity-Induced Functional Dyspepsia in Rats — https://europepmc.org/article/PMC/PMC13256725
- [8] A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia — https://clinicaltrials.gov/study/NCT07107334
- [9] Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome — https://pubmed.ncbi.nlm.nih.gov/42734711/
- [10] Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity — https://pubmed.ncbi.nlm.nih.gov/42687799/
- [11] Digestive Hormones and Their Impact on Bariatric and Pharmacologic Weight-Loss Therapies — https://pubmed.ncbi.nlm.nih.gov/42584007/
- [12] How cholecystectomy and gastrectomy contribute to pancreatic cancer development: a review — https://pubmed.ncbi.nlm.nih.gov/42724911/